# US 2019/0315816 A1 · Protransducine-c: gene transfer activator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315816 A1
- Document ID: US20190315816A1
- Status: Published application
- Kind: A1
- Application number: 16/347,762
- Filed: 2017-11-08
- Published: 2019-10-17
- Earliest claimed: 2016-11-09
- Applicants: Pharis Biotec GmbH
- Inventors: Wolf-Georg FORSSMANN; Rudolf RICHTER
- Web page: https://patentgrep.com/patent/US20190315816A1

## CPC

- C07K 14/16: HIV-1 {; HIV-2}
- C07K 14/435: from animals; from humans
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Polypeptide having the sequence

## Claims

### Claim 1

A polypeptide having a sequence similarity of at least 80% with the sequence
wherein
Z1 or Z3 have the same meaning or independently represent the N-terminal end of the polypeptide, or independently are the amino acids Leu or Ser or the following peptides
Ser-Asn, Ser-Asn-Asn, Ser-Asn-Asn-Ile, Ser-Asn-Asn-Ile-Thr, Thr-Leu, Ile-Thr-Leu, Asn-Ile-Thr-Leu, Asn-Asn-Ile-Thr-Leu, or Ser-Asn-Asn-Ile-Thr-Leu,
Z2 or Z4 have the same meaning or independently represent the C-terminal end of the polypeptide, or independently are the amino acids Gly or Glu or the following peptides
Glu-Val, Glu-Val-Gly, Glu-Val-Gly-Lys, Glu-Val-Gly-Lys-Ala, Glu-Val-Gly-Lys-Ala-Met, Glu-Val-Gly-Lys-Ala-Met-Tyr, Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala, Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro, Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro, Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile, Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Glu, Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Glu-Gly, Glu-Gly, Ile-Glu-Gly, Pro-Re-Glu-Gly, Pro-Pro-Ile-Glu-Gly, Ala-Pro-Pro-Ile-Glu-Gly, Tyr-Ala-Pro-Pro-Ile-Glu-Gly, Met-Tyr-Ala-Pro-Pro-Ile-Glu-Gly, Ala-Met-Tyr-Ala-Pro-Pro-Ile-Glu-Gly, Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Glu-Gly, Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Glu-Gly, Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Glu-Gly, or Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Glu-Gly.

### Claim 2 (depends on 1)

The polypeptide according to claim 1, wherein said dimer is formed from homologous or heterologous monomers.

### Claim 3 (depends on 1)

The polypeptide according to claim 1, having the amino acid sequence

### Claim 4 (depends on 1)

The polypeptide according to claim 1, to comprising a sequence of at least 80% similarity with the sequence

### Claim 5 (depends on 1)

The polypeptide according to claim 1, wherein at least one N-terminal end of the two amino acid chains forming the polypeptide is modified with a chemical group selected from the group consisting of one or two alkyl groups, such as methyl, ethyl, propyl or butyl groups, an acyl group, an acetyl or propionyl group, or the amino acid pyroglutamic acid forms the N-terminal end.

### Claim 6 (depends on 1)

An auxiliary agent for the precipitation of viruses, containing a polypeptide according to claim 1.

### Claim 7 (depends on 1)

A medicament comprising a polypeptide according to claim 1.

### Claim 8 (depends on 1)

A method of gene therapy comprising administering to a patient a polypeptide of claim 1 to treat a genetically caused disease.

### Claim 9 (depends on 1)

A process for enhancing the infection of a cell with a virus, comprising the steps of:
providing the polypeptide according to claim 1 dissolved in an organic solvent;
adding the polypeptide to an aqueous solution to form insoluble aggregates of the polypeptide;
mixing the solution from the preceding step; and
culturing cells in the presence of a polypeptide claim 1.

### Claim 10 (depends on 1)

A method of enhancing infection of a cell with a virus comprising exposing a cell to a virus and the polypeptide of claim 1 to enhance infection of the cell with the virus.

### Claim 11 (depends on 1)

A composition containing a polypeptide according to claim 1.
